RSDpress April 2016

Introducing WuXi’s Research Service Division

Dear Readers,
I am pleased to announce the establishment of a new WuXi business division, the Research Service Division (RSD), aimed at providing better support to our partners and promoting efficiency and collaboration between WuXi’s business units. RSD combines WuXi’s capability and technology platform in chemistry and biology to provide open access and integrated service for drug discovery and research. The services included in the new RSD are the International Discovery Service Unit (IDSU), Chemistry Service Unit (CSU), Oncology Unit, the Immunology Center, and Biology Unit (which includes HTS, in vitro screening, infectious disease, neurosciences, CV, and metabolism). This new integration will provide closer points of contacts for our partners and discovery teams, streamline the exceptional services offered across our platform, and enhance efficiency and productivity to drug discovery. We will focus on boosting our scientific capabilities and leading technology development to maintain WuXi’s industry leading position in research service. I look forward to continuing to provide outstanding service to our partners through this new initiative and connecting to our broader discovery community through the new RSDpress!
Best regards,
Steve Yang
Breaking RSD News

WuXi Acquires Crelux
WuXi Webinar: Tackling the Number 1 Drug Product Development Problem: Solubility

WuXi’s upcoming live global webcast, “Tackling the # 1 Drug Product Development Problem: Solubility” will take place on Thursday, May 5, 2016 (10AM PST | 1PM EST | 6PM GMT)
 
Our distinguished speakers include:
Mui Cheung, Director, Medicinal Chemistry, GlaxoSmithKline
Manish Gupta, Head of Biopharmaceutics, Platform Technologies & Science, GlaxoSmithKline
Matt Burke, Head of Drug Delivery, Platform Technologies & Science, GlaxoSmithKline
Riccardo Panicucci, Vice President, Pharmaceutical Development Services, WuXi AppTec
Richard Soll, SVP, International Discovery Service Unit, WuXi AppTec (moderator)
Submit your questions in advance for the speakers during registration!
We look forward to welcoming you to this lively discussion.
Innovation That Matters

Placing ‘Early’ Bets in Biotech – A Chat With Andy Schwab, Co-Founder & Managing Partner, 5AM Ventures

Next Generation Immuno-Oncology: Creating a New Pathway to ‘Eat’ Cancer – A Chat with Jonathan MacQuitty, CEO, Forty Seven

Connecting the Global Autism Scientific Community – A Chat With Alan Packer, Senior Scientist, Simons Foundation Autism Research Initiative

Finding Solutions to Rare Diseases through Genomics: An Interview with Hannes Smárason, WuXi NextCODE

How ‘Cool’ Science Translates Into Successful Companies – A Chat with UNITY Biotechnology CEO, Nathaniel David

The Future of Cancer Therapy: An Interview with Yinon Ben-Neriah, Hebrew University

WuXi News

Global WuXi Webinar: Pioneering Approaches to Dismantling Cancer

Juno Therapeutics and WuXi Start New Company to Develop Novel Cell-Based Cancer Immunotherapies in China

WuXi Lab Testing Division’s Analytical and Stability Testing Facilities Passed FDA Inspection

WuXi Opens Office in South Korea

WuXi Spring Reception in San Francisco

WuXi Releases New Mobile App for Compounds Sourcing

Huawei and WuXi Join Forces to Create China Precision Medicine Cloud Platform

Prima BioMed and WuXi Biologics Announce First Dose of Chinese-Manufactured Biologics in EU Clinical Trial

World’s Largest Autism Dataset Goes Online

WuXi NextCODE Becomes the First and Only CAP, CLIA, and California Accredited Sequencing Laboratory in China

WuXi’s STA Subsidiary Opens New Campus in Changzhou

WuXi Biologics Congratulates Ambrx and ZMC for Successful Dosing of a Novel Antibody-Drug Conjugate in Australia
In This Issue
Industry Beats

Pfizer Taps IBM for Research Collaboration to Transform Parkinson’s Disease Care (Source: Pfizer)Stanford Scientists Resurrect an Abandoned Drug and Find it Effective Against Two Human Viruses in a Lab Dish, with Potential to Fight Many More (Source: Stanford University)

Scientists Distinguish Molecules Most Capable of Fighting Prostate Cancer (Moscow Institute of Physics and Technology)

Aduro Biotech Helps Launch New Immunotherapy, Vaccine Effort (Source: University of California, Berkeley)


TESARO and MD Anderson Cancer Center Announce Immuno-Oncology Collaboration and Exclusive License Agreement (Source: Tesaro)

Johnson & Johnson Innovation Launches JLINX: A New Company Incubation Model Located at the Janssen Campus in Belgium (Source: Johnson & Johnson)

Allergan and Heptares Announce Global R&D and Commercialization Partnership for Novel Treatments in Alzheimer’s and Other Neurological Disorders (Source: Allergan)

GSK and Miltenyi Biotec Establish Cell and Gene Therapy Collaboration (Source: GSK)

Blueprint Medicines Announces Worldwide Collaboration to Accelerate and Expand its Development of Novel Medicines in the Field of Cancer Immunotherapy (Source: Blueprint Medicines)

Bristol-Myers Squibb to Acquire Padlock Therapeutics, Inc. (Source: Bristol-Myers Squibb)

Horizon Discovery Group plc Enters Immuno-Oncology Therapeutic Development and Forms Joint Venture with Centauri Therapeutics Limited (Source: Avvinity)

Johnson & Johnson Innovation Unveils JLABS @ TMC to Help Catalyze Early Stage Research through to Commercialization for Healthcare Solutions in Houston (Source: Johnson & Johnson)

Cancer Metabolism Company Metabomed Completes $18 Million Series A Financing (Source: PR Newswire)

Amal Therapeutics Raises CHF 3 Million in a Series A Financing Round Led by Boehringer Ingelheim Venture Fund (Source: Amal Therapeutics)

Gadeta Closes EUR 7 Million Series A Financing to Advance Novel Cancer Immunotherapies to the Clinic (Source: Yahoo Finance)

ImmunoMet Therapeutics Raises $5.2 million in a Series A Financing (Source: PR Newswire)

FDA Updates

Upcoming Events

May 11-12, 2016
Berlin, Germany
 
May 13-17, 2016
Seattle, WA
 
May 18-19, 2016
Congress 2016
London, U.K.
 
May 19-20, 2016
London, U.K.
 
May 29 – June 1, 2016
Heidelberg, Germany
May 30-June 2, 2016
Montreal, Canada
 
June 1-2, 2016
San Diego, CA
RSD Collaborator Publications

Two Scalable Syntheses of (S)-2-Methylazetidine. (Journal of Organic Chemistry)
In Case You Missed It

Medicinal Chemistry

 

G protein-coupled receptors as targets for anti-diabetic therapeutics. (Nature Review Drug Discovery)

 
 
Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer.(Nature Medicine)

 










Synthetic Chemistry

Dual C-F, C-H Functionalization via Photocatalysis: Access to Multifluorinated Biaryls. (Journal of the American Chemical Society) 

Network Analysis Guided Synthesis of Weisaconitine D and Liljestrandinine. (Nature)

Practical Ni-Catalyzed Aryl-Alkyl Cross-Coupling of Secondary Redox-Active Esters. (Journal of the American Chemical Society)

Strain-release amination. (Science)

Aryl Nitriles from Alkynes Using tert-Butyl Nitrite: Metal-Free Approach to C≡C Bond Cleavage. (ACS Organic Letters)

An Improved System for the Aqueous Lipshutz-Negishi Cross-Coupling of Alkyl Halides with Aryl Electrophiles.(Angewandte Chemie)

Access to Difluoromethylated Arenes by Pd-Catalyzed Reaction of Arylboronic Acids with Bromodifluoroacetate. (ACS Organic Letters)

 
Follow us on TwitterView our profile on LinkedIn